SUN PHARMACEUTICAL INDUSTRIES LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,460 INR | +0.05% |
|
-1.81% | +15.91% |
| May. 27 | Indian drugmakers to see FY25 revenue boost in key US market, says India Ratings and Research | RE |
| May. 25 | Sun Pharma to Pursue M&A | CI |
| Sales 2024 | 485B 5.81B | Sales 2025 * | 535B 6.41B | Capitalization | 3,503B 41.99B |
|---|---|---|---|---|---|
| Net income 2024 | 95.76B 1.15B | Net income 2025 * | 110B 1.32B | EV / Sales 2024 | 8.02 x |
| Net cash position 2024 * | 97.98B 1.17B | Net cash position 2025 * | 141B 1.69B | EV / Sales 2025 * | 6.28 x |
| P/E ratio 2024 |
40.6
x | P/E ratio 2025 * |
31.8
x | Employees | 41,000 |
| Yield 2024 * |
0.85% | Yield 2025 * |
0.96% | Free-Float | 45.31% |
More Fundamentals
* Assessed data
More news
Latest transcript on Sun Pharmaceutical Industries Ltd.
More recommendations
More press releases
More news
| 1 day | +0.05% | ||
| 1 week | -1.81% | ||
| 1 month | -2.82% | ||
| 3 months | -7.49% | ||
| 6 months | +19.08% | ||
| Current year | +15.91% |
1 week
1 440.00
1 501.00
1 month
1 440.001 564.00
Current year
1 257.151 638.85
1 year
977.301 638.85
3 years
652.701 638.85
5 years
312.001 638.85
10 years
312.001 638.85
| Managers | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Founder | 68 | 81-12-31 | |
| Director of Finance/CFO | - | 17-06-18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 68 | 81-12-31 | |
Rama Bijapurkar
BRD | Director/Board Member | 67 | 21-05-20 |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 23-06-14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.72% | 6 M€ | +6.07% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 1,460 | +0.05% | 5,503,924 |
| 24-05-30 | 1,459 | -1.34% | 3,133,423 |
| 24-05-29 | 1,479 | +0.96% | 2,843,365 |
| 24-05-28 | 1,465 | -0.08% | 2,616,438 |
| 24-05-27 | 1,466 | -1.39% | 3,474,806 |
Delayed Quote NSE India S.E., May 31, 2024 at 07:43 am EDT
More quotes
Sun Pharmaceutical Industries Ltd. is one of the Indian leaders of pharmaceutical groups. Net sales break down by family of products as follows:
- generic and OTC medicines (94%): for cardiologic, psychiatric, neurological, gastroenterological, diabetic and respiratory diseases treatment;
- other (6%) : primarily active pharmaceutical ingredients.
At the end of March 2021, the group had 44 production plants worldwide.
Net sales are distributed geographically as follows: India (33%), the United States (31.3%), other (35.7%).
Sector
Pharmaceuticals
Calendar
2024-06-03
- BofA India Conference
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
37
Last Close Price
1,460
INR
Average target price
1,595
INR
Spread / Average Target
+9.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.91% | 41.97B | |
| +22.40% | 22.34B | |
| +18.48% | 15.25B | |
| +16.12% | 14B | |
| +45.12% | 12.06B | |
| -0.05% | 6.79B | |
| -9.58% | 6.8B | |
| -8.87% | 5.73B | |
| +14.18% | 5.49B | |
| +4.17% | 4.62B |
- Stock Market
- Equities
- SUNPHARMA Stock
